Citigroup Boosts Shattuck Labs Price Target to $7.00

Analysts raise price target for biotech company Shattuck Labs, citing potential upside.

Mar. 13, 2026 at 8:33pm

Got story updates? Submit your updates here. ›

Citigroup analysts have increased their price target for shares of Shattuck Labs (NASDAQ:STTK) from $4.00 to $7.00, while maintaining a "neutral" rating on the stock. Several other equity analysts have also recently issued reports on Shattuck Labs, with some upgrading the stock to "buy" ratings and higher price targets.

Why it matters

The increased price target from Citigroup and other positive analyst sentiment suggests potential upside for Shattuck Labs, a clinical-stage biotech company focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, particularly opioid addiction.

The details

Citigroup cited the company's progress and potential in its research note, raising the price target by 75% to $7.00 per share. Other analysts, including those from HC Wainwright, Wedbush, and Needham & Company, have also issued more bullish ratings and higher price targets for Shattuck Labs in recent months.

  • Citigroup issued the updated price target and rating on Friday, March 13, 2026.

The players

Citigroup

A multinational investment bank and financial services corporation.

Shattuck Labs

A clinical-stage biotechnology company focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, particularly opioid addiction.

Got photos? Submit your photos here. ›

The takeaway

The increased price target and positive analyst sentiment around Shattuck Labs suggests the company's immunotherapeutic vaccine development efforts are gaining traction, which could be an important step in addressing the ongoing opioid crisis.